Microbiome Movement - Drug Development Europe 2021
January 27 - 29, 2021 - GBHanson Wade
info@hansonwade.com
Phone:+16174554188
As the first microbiome-based therapeutic steps closer to market approval, the scientific community continue to demonstrate the functional role of the human microbiome as a novel source of therapeutic, biomarker and diagnostic development. Despite this progress, the vast potential to develop effective treatments that target the human microbiome is still limited by the complex challenges in developing them. Part of the foremost conference series for microbiome researchers in industry, the 5th Microbiome Movement - Drug Development Europe 2021 will return to unite leading scientists from the biopharmaceutical and academic community to pursue the causal role of the microbiome in disease, and help create a new generation of microbiome-targeted therapeutics with predictable modes of action and consistent clinical outcomes.